TACSTD2 and neoplasm: Among the three potential candidates TROP2, CEACAM5 and CD138 that were analyzed further, TROP2 shows the most promising protein expression as it shows a high protein expression over all tumor stages and might even be an interesting therapeutic candidate for earlier stages.